| abstract |
The present invention belongs to the field of immunotherapy of autoimmune diseases and relates to a humanized monoclonal antibody that binds IL17A. The present invention discloses a nucleic acid sequence encoding said antibody (including heavy/light chain variable regions), a vector containing said nucleic acid sequences, a pharmaceutical composition and a kit. Said monoclonal antibody is capable of specifically binding IL17A protein with high affinity, has a strong ability to block the binding of IL17A, IL17A/F with receptor IL17RA. Compared with comparable drugs, said antibody has superior or equivalent ability to block IL17A and IL17A/F induced - inflammatory cytokine secretion of human epidermal fibroblasts HFF; in a mouse psoriasis model, said antibody also showed significantly better in vivo efficacy than comparable drugs, and the administration of said antibody significantly reduced PASI scores; in the cynomolgus monkey efficacy study, said humanized antibody demonstrated superior pharmacokinetics, including rapid absorption after subcutaneous injection, long half-life, and better drug exposure, etc., laying the foundation for longer dosing cycles. The humanized monoclonal antibody of the present invention can be used for the treatment of psoriasis, etc. |